Featured Research

from universities, journals, and other organizations

Low molecular weight heparin use in cancer treatment

Date:
February 15, 2012
Source:
McMaster University
Summary:
Researchers suggest conclusive answers to key questions on the benefits of low molecular weight heparin (LMWH) for cancer patients remain elusive - despite promising results from large studies.

For decades, the blood thinner heparin has been used to prevent and treat blood clots. Could it be just as effective in treating cancer?

In an editorial published February 15 in the New England Journal of Medicine, researchers from McMaster University and the University at Buffalo suggest conclusive answers to key questions on the benefits of low molecular weight heparin (LMWH) for cancer patients remain elusive -- despite promising results from large studies.

Co-authors of the editorial are Dr. Elie Akl, associate professor in the Department of Medicine in UB's School of Medicine and Biomedical Sciences and in McMaster University's Department of Clinical Epidemiology and Biostatistics, and Dr. Holger Schünemann, professor of medicine and chair of the Department of Clinical Epidemiology and Biostatistics, McMaster University.

In their editorial, on a paper in the same issue of the journal, the physicians say the anti-clotting effect of heparin is well established, unlike a speculated anti-tumor effect. Consequently, they question if heparin should be offered to cancer patients who don't have clotting problems.

Having systematically summarized the available evidence of how cancer patients may benefit from heparin in a 2011 Cochrane Review, they now were invited to comment on the SAVE-ONCO study of 3,200 patients with metastatic or locally advanced solid tumors. Patients receiving chemotherapy were also given a preventive dose of semuloparin (ultra-low-molecular weight heparin) once daily for just over three months.

This study, the largest so far, found semuloparin significantly reduced the incidence of thromboembolism but had no statistically significant effect on major bleeding and death. Taken together with the prior studies and another study they recently identified these findings confirm and further establish the authors' recent review's conclusion of "a likely small survival benefit."

They estimated "if 1,000 patients with cancer were to use a prophylactic dose of LMWH, approximately 30 would avert death, 20 would avert a clotting complication and one would suffer a major bleeding episode over a 12-month period."

Akl and Schünemann said the findings have meaning for both patients and other healthcare decision makers.

"Patients who are not bothered much by daily injections of LMWH can avert hospitalizations for a clotting complication and possibly achieve a prolongation of life if they accept an increased risk of bleeding and its subsequent treatment," they said.

They added that those patients truly looking for survival from their cancer will need to deal with "some uncertainty" about whether their type and stage of cancer are associated with the likely survival benefit of LMWH.

Akl and Schünemann said more clarity is required about which cancer patients would benefit most, the magnitude of this survival benefit, and whether this benefit is appropriate for cancers that respond poorly to other therapies. They are planning a sophisticated analysis of the published trials (individual patient data meta-analysis) to investigate these questions.


Story Source:

The above story is based on materials provided by McMaster University. Note: Materials may be edited for content and length.


Journal Reference:

  1. Elie A. Akl, Holger J. Schünemann. Routine Heparin for Patients with Cancer? One Answer, More Questions. New England Journal of Medicine, 2012; 366 (7): 661 DOI: 10.1056/NEJMe1113672

Cite This Page:

McMaster University. "Low molecular weight heparin use in cancer treatment." ScienceDaily. ScienceDaily, 15 February 2012. <www.sciencedaily.com/releases/2012/02/120215185838.htm>.
McMaster University. (2012, February 15). Low molecular weight heparin use in cancer treatment. ScienceDaily. Retrieved July 31, 2014 from www.sciencedaily.com/releases/2012/02/120215185838.htm
McMaster University. "Low molecular weight heparin use in cancer treatment." ScienceDaily. www.sciencedaily.com/releases/2012/02/120215185838.htm (accessed July 31, 2014).

Share This




More Health & Medicine News

Thursday, July 31, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Dangerous Bacteria Kills One in Florida

Dangerous Bacteria Kills One in Florida

AP (July 31, 2014) — Sarasota County, Florida health officials have issued a warning against eating raw oysters and exposing open wounds to coastal and inland waters after a dangerous bacteria killed one person and made another sick. (July 31) Video provided by AP
Powered by NewsLook.com
Health Insurers' Profits Slide

Health Insurers' Profits Slide

Reuters - Business Video Online (July 30, 2014) — Obamacare-related costs were said to be behind the profit plunge at Wellpoint and Humana, but Wellpoint sees the new exchanges boosting its earnings for the full year. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com
Peace Corps Pulls Workers From W. Africa Over Ebola Fears

Peace Corps Pulls Workers From W. Africa Over Ebola Fears

Newsy (July 30, 2014) — The Peace Corps is one of several U.S.-based organizations to pull workers out of West Africa because of the Ebola outbreak. Video provided by Newsy
Powered by NewsLook.com
Weather Kills 2K A Year, But Storms Aren't The Main Offender

Weather Kills 2K A Year, But Storms Aren't The Main Offender

Newsy (July 30, 2014) — Health officials say 2,000 deaths occur each year in the U.S. due to weather, but it's excessive heat and cold that claim the most lives. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

    Environment News

    Technology News



      Save/Print:
      Share:  

      Free Subscriptions


      Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

      Get Social & Mobile


      Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

      Have Feedback?


      Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
      Mobile iPhone Android Web
      Follow Facebook Twitter Google+
      Subscribe RSS Feeds Email Newsletters
      Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins